Pharmacokinetics
Pharmacokinetic data after single and multiple dosing in part 1 phase 1a are summarized in Supplementary Table In part 1 phase 1b, the concentration–time profiles of arms 1–3 (nofazinlimab 200 mg Q3W) were comparable, whereas arm 4 (400 mg Q6W) had a higher CIn part 2a, no changes in nofazinlimab systemic exposure (C